HST Global Announces Formalization of Protocol Licensing for International Partnerships

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced that it has finalized the formal licensing model that will be used by our international partners in the development of our Clinical Treatment Facilities worldwide.

As previously announced, HST Global Inc. (HST) has partnered with Health Matters International (HMI), a Canadian Company that has vast international knowledge in the Healthcare Industry. Through this association, HMI identified Panama and Costa Rica as potential countries for the development of HST’s Clinical Treatment Facilities which features the company’s “FIT” protocol. Doctors that will have a role as part of the initial medical team in these clinics recently visited the prototype facility in Reno.

Licensing fees will range between $250,000 and $500,000 and will be measured against the “drawing” population of the location. While other factors will be involved in each individual country such as demographic data and economic circumstances, the fee will incorporate training, initial products and onsite development for each respective team. In addition, HST will be paid a royalty amount for each application of the Company’s protocol.

Mr. Ron Howell, CEO and President of HST Global, Inc., stated, “We are pleased with the progress we have made formalizing our licensing model for our global partners. Greg and his team at HMI are ready to introduce this successful protocol to patients in both Panama and Costa Rica. HST has received a number of international inquires regarding the opening of clinics. While the completion of this formal licensing model will allow the company to proceed with these opportunities, the major consideration is facilitating growth with continuity in presentation and application of the “FIT” protocol to ensure maximum success among the community of patients we serve.”

Mr. Wes Tate, CFO of HST Global, Inc., stated, “It is exciting to see the results of the efforts required to transition HST from a development stage company to a revenue producing endeavor. The Company has spent the past several months grooming relationships, investing in research and development, and implementation of our overall strategic plan. With the finalization of our worldwide licensing model, we will commence the next phase of our strategy via international growth and at the same time continually substantiate shareholder value.”

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.